Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2016

Open Access 01-12-2016 | Review

Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis

Authors: Michele Iudici, Pierre Quartier, Benjamin Terrier, Luc Mouthon, Loïc Guillevin, Xavier Puéchal

Published in: Orphanet Journal of Rare Diseases | Issue 1/2016

Login to get access

Abstract

Background

The data from cohorts of childhood-onset granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) remain scarce and heterogeneous. We aimed to analyse the features at presentation, therapeutic approaches and the disease course of these rare diseases.

Methods

Electronic searches of Medline and the Cochrane Central Register of Controlled trials database were conducted. We also checked the reference lists of the studies included and other systematic reviews, to identify additional reports. We included all cohorts, cross-sectional studies or registries reporting features at presentation or outcomes in patients with a diagnosis of childhood-onset GPA or MPA (age <18 years). The pooled prevalence of clinical manifestations at presentation, ANCA and induction therapies for GPA and MPA was calculated.

Results

We reviewed 570 full texts and identified 14 studies on GPA and 8 on MPA. Childhood-onset GPA and MPA occurred predominantly in female subjects during adolescence. For GPA, ear-nose-throat (ENT) disease (pooled prevalence 82 % [95 % CI 78–87]), constitutional symptoms (73 % [95 % CI 55–88]), renal (65 % [95 % CI 49–79]), and lower respiratory tract (61 % [95 % CI 48–74]) manifestations were the most frequently reported at presentation. Renal disease was a hallmark of MPA (94 % [95 % CI 89–97]). ANCA were detected in >90 % of children with GPA or MPA. Combined corticosteroids and cyclophosphamide was the most frequently used first remission-inducing treatment for GPA (76 % [95 % CI 69–82]) and MPA (62 % [95 % CI 20–96]). Relapses occurred more frequently in GPA (67–100 %) than in MPA (25–50 %). The leading causes of death were the disease itself, and infections.

Conclusions

Childhood-onset MPA and GPA remain severe diseases with frequent relapses and a high cumulative morbidity. Survival and disease-free survival need to be improved.
Appendix
Available only for authorised users
Literature
1.
go back to reference Denardo BA, Tucker LB, Miller LC, et al. Demography of a regional pediatric rheumatology patient population. Affiliated Children’s arthritis centers of New England. J Rheumatol. 1994;21:1553–61.PubMed Denardo BA, Tucker LB, Miller LC, et al. Demography of a regional pediatric rheumatology patient population. Affiliated Children’s arthritis centers of New England. J Rheumatol. 1994;21:1553–61.PubMed
2.
go back to reference Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian pediatric rheumatology association disease registry. J Rheumatol. 1996;23:1981–7.PubMed Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian pediatric rheumatology association disease registry. J Rheumatol. 1996;23:1981–7.PubMed
3.
go back to reference Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the united states: results of a 3 year survey. Pediatric rheumatology database research group. J Rheumatol. 1996;23:1968–74.PubMed Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the united states: results of a 3 year survey. Pediatric rheumatology database research group. J Rheumatol. 1996;23:1968–74.PubMed
4.
go back to reference Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–41.CrossRefPubMed Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–41.CrossRefPubMed
5.
go back to reference Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum. 2007;57:837–44.CrossRefPubMed Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum. 2007;57:837–44.CrossRefPubMed
6.
go back to reference Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum. 2009;60:3413–24.CrossRefPubMed Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum. 2009;60:3413–24.CrossRefPubMed
7.
8.
go back to reference Fowler NM, Beach JM, Krakovitz P, et al. Airway manifestations in childhood granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res (Hoboken). 2012;64:434–40.CrossRef Fowler NM, Beach JM, Krakovitz P, et al. Airway manifestations in childhood granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res (Hoboken). 2012;64:434–40.CrossRef
9.
go back to reference Bohm M, Gonzalez Fernandez MI, Ozen S, et al. Clinical features of childhood granulomatosis with polyangiitis (Wegener’s granulomatosis). Pediatr Rheumatol Online J. 2014;12:18.CrossRefPubMedPubMedCentral Bohm M, Gonzalez Fernandez MI, Ozen S, et al. Clinical features of childhood granulomatosis with polyangiitis (Wegener’s granulomatosis). Pediatr Rheumatol Online J. 2014;12:18.CrossRefPubMedPubMedCentral
10.
go back to reference Kosalka J, Bazan-Socha S, Ignacak M, et al. Clinical manifestation of pediatric granulomatosis with polyangiitis - the experience of two regions in Poland. Folia Med Cracov. 2014;54:5–12.PubMed Kosalka J, Bazan-Socha S, Ignacak M, et al. Clinical manifestation of pediatric granulomatosis with polyangiitis - the experience of two regions in Poland. Folia Med Cracov. 2014;54:5–12.PubMed
11.
go back to reference Iudici M, Puéchal X, Pagnoux C, et al. Childhood-onset systemic necrotizing vasculitides: long-term data from the French vasculitis study group registry. Arthritis Rheumatol. 2015;67:1959–65.CrossRefPubMed Iudici M, Puéchal X, Pagnoux C, et al. Childhood-onset systemic necrotizing vasculitides: long-term data from the French vasculitis study group registry. Arthritis Rheumatol. 2015;67:1959–65.CrossRefPubMed
12.
go back to reference Sacri AS, Chambaraud T, Ranchin B, et al. Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrol Dial Transplant. 2015;30 Suppl 1:i104–12.PubMed Sacri AS, Chambaraud T, Ranchin B, et al. Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrol Dial Transplant. 2015;30 Suppl 1:i104–12.PubMed
13.
go back to reference Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.CrossRefPubMed Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.CrossRefPubMed
14.
go back to reference Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605–17.CrossRefPubMed Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605–17.CrossRefPubMed
15.
go back to reference Shamliyan TA, Kane RL, Ansari MT, et al. Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol. 2011;64:637–57.CrossRefPubMed Shamliyan TA, Kane RL, Ansari MT, et al. Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol. 2011;64:637–57.CrossRefPubMed
16.
go back to reference Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101–5.CrossRefPubMedPubMedCentral Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101–5.CrossRefPubMedPubMedCentral
17.
go back to reference Orlowski JP, Clough JD, Dyment PG. Wegener’s granulomatosis in the pediatric age group. Pediatrics. 1978;61:83–90.PubMed Orlowski JP, Clough JD, Dyment PG. Wegener’s granulomatosis in the pediatric age group. Pediatrics. 1978;61:83–90.PubMed
19.
go back to reference Stegmayr BG, Gothefors L, Malmer B, et al. Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatr Nephrol. 2000;14:208–13.CrossRefPubMed Stegmayr BG, Gothefors L, Malmer B, et al. Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatr Nephrol. 2000;14:208–13.CrossRefPubMed
20.
go back to reference Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol. 2002;17:754–61.CrossRefPubMed Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol. 2002;17:754–61.CrossRefPubMed
21.
go back to reference Tahghighi F, Moradinejad MH, Aghighi Y, et al. Evaluation of 10-year experience of Wegener’s granulomatosis in Iranian children. ISRN Rheumatol. 2013;2013:694928.CrossRefPubMedPubMedCentral Tahghighi F, Moradinejad MH, Aghighi Y, et al. Evaluation of 10-year experience of Wegener’s granulomatosis in Iranian children. ISRN Rheumatol. 2013;2013:694928.CrossRefPubMedPubMedCentral
22.
go back to reference Gajic-Veljic M, Nikolic M, Peco-Antic A, et al. Granulomatosis with polyangiitis (Wegener’s granulomatosis) in children: report of three cases with cutaneous manifestations and literature review. Pediatr Dermatol. 2013;30:e37–42.CrossRefPubMed Gajic-Veljic M, Nikolic M, Peco-Antic A, et al. Granulomatosis with polyangiitis (Wegener’s granulomatosis) in children: report of three cases with cutaneous manifestations and literature review. Pediatr Dermatol. 2013;30:e37–42.CrossRefPubMed
23.
go back to reference Rottem M, Fauci AS, Hallahan CW, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr. 1993;122:26–31.CrossRefPubMed Rottem M, Fauci AS, Hallahan CW, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr. 1993;122:26–31.CrossRefPubMed
24.
go back to reference Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham vasculitis activity score. International network for the study of the systemic vasculitides (INSSYS). Arthritis Rheum. 2001;44:912–20.CrossRefPubMed Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham vasculitis activity score. International network for the study of the systemic vasculitides (INSSYS). Arthritis Rheum. 2001;44:912–20.CrossRefPubMed
25.
go back to reference Bakkaloglu A, Ozen S, Baskin E, et al. The significance of antineutrophil cytoplasmic antibody in microscopic polyangitis and classic polyarteritis nodosa. Arch Dis Child. 2001;85:427–30.CrossRefPubMedPubMedCentral Bakkaloglu A, Ozen S, Baskin E, et al. The significance of antineutrophil cytoplasmic antibody in microscopic polyangitis and classic polyarteritis nodosa. Arch Dis Child. 2001;85:427–30.CrossRefPubMedPubMedCentral
26.
go back to reference Hattori M, Kurayama H, Koitabashi Y, et al. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J Am Soc Nephrol. 2001;12:1493–500.PubMed Hattori M, Kurayama H, Koitabashi Y, et al. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J Am Soc Nephrol. 2001;12:1493–500.PubMed
27.
go back to reference Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G, et al. Childhood microscopic polyangiitis associated with MPO-ANCA. Pediatr Nephrol. 2006;21:46–53.CrossRefPubMed Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G, et al. Childhood microscopic polyangiitis associated with MPO-ANCA. Pediatr Nephrol. 2006;21:46–53.CrossRefPubMed
28.
go back to reference Yu F, Huang JP, Zou WZ, et al. The clinical features of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese children. Pediatr Nephrol. 2006;21:497–502.CrossRefPubMed Yu F, Huang JP, Zou WZ, et al. The clinical features of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese children. Pediatr Nephrol. 2006;21:497–502.CrossRefPubMed
29.
go back to reference Sun L, Wang H, Jiang X, et al. Clinical and pathological features of microscopic polyangiitis in 20 children. J Rheumatol. 2014;41:1712–9.CrossRefPubMed Sun L, Wang H, Jiang X, et al. Clinical and pathological features of microscopic polyangiitis in 20 children. J Rheumatol. 2014;41:1712–9.CrossRefPubMed
30.
go back to reference Basu B, Mahapatra TK, Mondal N. Favourable renal survival in paediatric microscopic polyangiitis: efficacy of a novel treatment algorithm. Nephrol Dial Transplant. 2015;30 Suppl 1:i113–8.PubMed Basu B, Mahapatra TK, Mondal N. Favourable renal survival in paediatric microscopic polyangiitis: efficacy of a novel treatment algorithm. Nephrol Dial Transplant. 2015;30 Suppl 1:i113–8.PubMed
31.
go back to reference Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;16:488–98.CrossRef Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;16:488–98.CrossRef
32.
go back to reference Bligny D, Mahr A, Toumelin PL, et al. Predicting mortality in systemic Wegener’s granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004;51:83–91.CrossRefPubMed Bligny D, Mahr A, Toumelin PL, et al. Predicting mortality in systemic Wegener’s granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004;51:83–91.CrossRefPubMed
33.
go back to reference Halstead LA, Karmody CS, Wolff SM. Presentation of Wegener’s granulomatosis in young patients. Otolaryngol Head Neck Surg. 1986;94:368–71.CrossRefPubMed Halstead LA, Karmody CS, Wolff SM. Presentation of Wegener’s granulomatosis in young patients. Otolaryngol Head Neck Surg. 1986;94:368–71.CrossRefPubMed
34.
go back to reference Hall SL, Miller LC, Duggan E, et al. Wegener granulomatosis in pediatric patients. J Pediatr. 1985;106:739–44.CrossRefPubMed Hall SL, Miller LC, Duggan E, et al. Wegener granulomatosis in pediatric patients. J Pediatr. 1985;106:739–44.CrossRefPubMed
35.
go back to reference Cabral DA, Canter DL, Muscal E, et al. Comparing presenting clinical features of 48 children with microscopic polyangiitis (MPA) against 183 having granulomatosis with polyangiitis (GPA). An ARChiVe study. Arthritis Rheumatol. 2016. [Epub ahead of print]. Cabral DA, Canter DL, Muscal E, et al. Comparing presenting clinical features of 48 children with microscopic polyangiitis (MPA) against 183 having granulomatosis with polyangiitis (GPA). An ARChiVe study. Arthritis Rheumatol. 2016. [Epub ahead of print].
36.
go back to reference Lebovics RS, Hoffman GS, Leavitt RY, et al. The management of subglottic stenosis in patient with Wegener’s granulomatosis. Laryngoscope. 1992;102:1341–5.CrossRefPubMed Lebovics RS, Hoffman GS, Leavitt RY, et al. The management of subglottic stenosis in patient with Wegener’s granulomatosis. Laryngoscope. 1992;102:1341–5.CrossRefPubMed
37.
go back to reference Dolezalova P, Price-Kuehne FE, Özen S, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the paediatric vasculitis activity score (PVAS). Ann Rheum Dis. 2013;72:1628–33.CrossRefPubMed Dolezalova P, Price-Kuehne FE, Özen S, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the paediatric vasculitis activity score (PVAS). Ann Rheum Dis. 2013;72:1628–33.CrossRefPubMed
38.
go back to reference Puéchal X, Pagnoux C, Perrodeau É, et al. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis Rheumatol. 2016;68:690–701.CrossRefPubMed Puéchal X, Pagnoux C, Perrodeau É, et al. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis Rheumatol. 2016;68:690–701.CrossRefPubMed
39.
go back to reference Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370:921–31.CrossRefPubMed Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370:921–31.CrossRefPubMed
40.
go back to reference Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2006;66:222–7.CrossRefPubMedPubMedCentral Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2006;66:222–7.CrossRefPubMedPubMedCentral
Metadata
Title
Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis
Authors
Michele Iudici
Pierre Quartier
Benjamin Terrier
Luc Mouthon
Loïc Guillevin
Xavier Puéchal
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2016
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-016-0523-y

Other articles of this Issue 1/2016

Orphanet Journal of Rare Diseases 1/2016 Go to the issue